CEL-SCI Corp. (CVM)

1.89
0.02 1.02
AMEX : Health Technology
Prev Close 1.87
Open 1.90
Day Low/High 1.82 / 1.90
52 Wk Low/High 1.30 / 3.92
Volume 14.89K
Avg Volume 151.00K
Exchange AMEX
Shares Outstanding 16.50M
Market Cap 29.86M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016

CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016

CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD and Series EE warrants to July 1, 2018 (close of business).

CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results

CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2017.

CEL-SCI To Present Tomorrow At 2018 BIO CEO & Investor Conference

CEL-SCI To Present Tomorrow At 2018 BIO CEO & Investor Conference

CEL-SCI Corporation (NYSE American: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:45 a.

CEL-SCI To Present At 2018 BIO CEO & Investor Conference

CEL-SCI To Present At 2018 BIO CEO & Investor Conference

CEL-SCI Corporation (NYSE American: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:45 a.

U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology

U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology

CEL-SCI Corporation (NYSE American: CVM) today announced the U.S.

IIROC Trading Resumption - CVM

IIROC Trading Resumption - CVM

IIROC Trading Halt - CVM

IIROC Trading Halt - CVM

CEL-SCI Announces Adjustment To Warrant Exercise Price

CEL-SCI Announces Adjustment To Warrant Exercise Price

CEL-SCI Corporation (NYSE American: CVM) announced today that the outstanding Series S warrants (CUSIP number 150837177) that are publicly traded under the symbol "CVM WS" on the NYSE American have been repriced to $3.

CEL-SCI Awarded Patent For LEAPS Vaccine In Treatment Of Rheumatoid Arthritis

CEL-SCI Awarded Patent For LEAPS Vaccine In Treatment Of Rheumatoid Arthritis

CEL-SCI Corporation (NYSE American: CVM) today announced that the European Patent Office has issued CEL-SCI patent EP 2254588B1 titled, "Method of Preparation and Composition of Peptide Constructs for Treatment of...

CEL-SCI Issues Letter To Shareholders

CEL-SCI Issues Letter To Shareholders

CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.

CEL-SCI Reports Fiscal 2017 Financial Results And Clinical & Corporate Developments

CEL-SCI Reports Fiscal 2017 Financial Results And Clinical & Corporate Developments

CEL-SCI Corporation (NYSE American: CVM) reported financial results today for the fiscal year ended September 30, 2017.

CEL-SCI Announces Robert Watson Joins Its Board Of Directors

CEL-SCI Announces Robert Watson Joins Its Board Of Directors

CEL-SCI Corporation ( NYSE American: CVM) announced today that healthcare information technology executive Robert Watson has joined the Company's Board of Directors.

CEL-SCI Reaches Full Enrollment In Pivotal Phase 3 Head And Neck Cancer Study

CEL-SCI Reaches Full Enrollment In Pivotal Phase 3 Head And Neck Cancer Study

CEL-SCI Corporation ( NYSE American: CVM) announced today that no further patient enrollment is required in the pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte...

CEL-SCI Reports Recent Data Review By The Independent Data Monitoring Committee For Its Pivotal Phase 3 Head And Neck Cancer Study

CEL-SCI Reports Recent Data Review By The Independent Data Monitoring Committee For Its Pivotal Phase 3 Head And Neck Cancer Study

CEL-SCI Corporation ( NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine*...

CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016

CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016

CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD and Series EE warrants to March 1, 2018 (close of business).

CEL-SCI Announces Update On Arbitration Against Former Clinical Research Organization

CEL-SCI Announces Update On Arbitration Against Former Clinical Research Organization

CEL-SCI Corporation ( NYSE American:CVM) announced today an update on its arbitration with its former clinical research organization (CRO).

CEL-SCI Granted European Patent For Multikine's Mechanism Of Action In Making Tumors 'Visible' To The Immune System

CEL-SCI Granted European Patent For Multikine's Mechanism Of Action In Making Tumors 'Visible' To The Immune System

CEL-SCI Corporation ( NYSE American: CVM ) announced today that the European Patent Office has issued a new patent to CEL-SCI for its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection),...

CEL-SCI Announces Update On Ongoing Arbitration Against Former Clinical Research Organization

CEL-SCI Announces Update On Ongoing Arbitration Against Former Clinical Research Organization

CEL-SCI Corporation ( NYSE American: CVM ) announced today that as it nears the conclusion of its arbitration with its former clinical research organization (CRO), the Company has restructured its agreement with the...

CEL-SCI Announces $1.5 Million NIH SBIR Grant To Support Development Of Rheumatoid Arthritis Vaccine

CEL-SCI Announces $1.5 Million NIH SBIR Grant To Support Development Of Rheumatoid Arthritis Vaccine

CEL-SCI Corporation ( NYSE American: CVM ) announced today that it has been awarded a new Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Arthritis and Musculoskeletal and Skin...

CEL-SCI To Present Today At The 19th Annual Rodman & Renshaw Global Investment Conference

CEL-SCI To Present Today At The 19th Annual Rodman & Renshaw Global Investment Conference

CEL-SCI Corporation (NYSE American: CVM), announces Geert Kersten, Chief Executive Officer, will present today at the 19th Annual Rodman & Renshaw Global Investment Conference at 2:10 PM.

CEL-SCI To Present At The 19th Annual Rodman & Renshaw Global Investment Conference On September 11, 2017

CEL-SCI To Present At The 19th Annual Rodman & Renshaw Global Investment Conference On September 11, 2017

CEL-SCI Corporation (NYSE American: CVM), today announced Geert Kersten, Chief Executive Officer, will be presenting at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.

CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016

CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016

CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD and Series EE warrants to December 1, 2017 (close of business).

CEL-SCI Announces $3.5 Million Registered Direct Offering

CEL-SCI Announces $3.5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE American:CVM) today announced it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $3.

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

U.S. FDA Removes Clinical Hold On CEL-SCI's Phase 3 Head & Neck Cancer Trial

U.S. FDA Removes Clinical Hold On CEL-SCI's Phase 3 Head & Neck Cancer Trial

CEL-SCI Corporation (NYSE American: CVM) today announced it has received a letter from the U.

CEL-SCI Extends The Expiration Date Of Series DD Warrants Issued In December 2016

CEL-SCI Extends The Expiration Date Of Series DD Warrants Issued In December 2016

CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD warrants by one month, from August 10, 2017 to September 10, 2017 (close of business).

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2017 Financial Results

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2017 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2017.

CEL-SCI Extends The Expiration Date Of Series DD Warrants Issued In December 2016

CEL-SCI Extends The Expiration Date Of Series DD Warrants Issued In December 2016

CEL-SCI Corporation (NYSE MKT:CVM) announces that it is extending the expiration date of its Series DD warrants by one month, from July 10, 2017 to August 10, 2017 (close of business).

TheStreet Quant Rating: D (Sell)